• 1
    Nies AS. Principles of therapeutics. In HardmanJG, LimbirdLE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001: 4566.
  • 2
    Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004; 126: 234S64S.
  • 3
    Müller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G, Eisert WG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990; 30: 17986.
  • 4
    FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 124757.
  • 5
    Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European stroke prevention study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 113.
  • 6
    Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 2027.
  • 7
    Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 539.
  • 8
    Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 2338.
  • 9
    Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 290813.
  • 10
    Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 7837.
  • 11
    Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction. Circulation 2003; 107: 327.
  • 12
    Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function – a flow cytometry study. Eur Heart J 2003; 24: 17449.
  • 13
    Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 16671.
  • 14
    Wienbergen H, Gitt AK, Schiele R, Juenger C, Heer T, Meisenzahl C, Limbourg P, Bossaller C, Senges J, MITRA PLUS Study Group. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atrovastatin versus other statin therapies. Am J Cardiol 2003; 92: 2858.
  • 15
    Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ, Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel – atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 9214.
  • 16
    Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 73: 98995.
  • 17
    Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 12230.
  • 18
    Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 16316.
  • 19
    O'Connor FF, Shields DC, Fitzgerald A, Cannon CP, Braunwald E, Fitzgerald DJ. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 325660.
  • 20
    Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with PlA2 polymorphysms. Am Heart J 2002; 143: 7682.
  • 21
    Meisel C, López JA, Stangl K. Role of platelet glycoprotein polymorphysms in cardiovascular diseases. Naunyn Schmiedeberg's Arch Pharmacol 2004; 369: 3854.
  • 22
    Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 180917.
  • 23
    Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. JACC 2005; in press.
  • 24
    Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors. Blood 1998; 92: 32409.
  • 25
    Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 15149.
  • 26
    Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Am J Cardiol 2000; 85: 4913.
  • 27
    Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 24655.
  • 28
    Vejar M, Fragasso G, Hackett D, Lipkin PD, Maseri A, Born GVR, Ciabattoni G, Patrono C. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina. Thromb Haemostas 1990; 63: 1638.
  • 29
    Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in unstable angina. Circulation 1997; 96: 110916.
  • 30
    Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T, Davì G, Cuccurullo F, Patrono C. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102: 100713.
  • 31
    Van Kooten F, Ciabattoni G, Koudstaal PJ, Grobbee DE, Kluft C, Patrono C. Increased thromboxane biosynthesis is associated with post-stroke dementia. Stroke 1999; 30: 15427.
  • 32
    Rocca B, Secchiero P, Ciabattoni G, Ranelletti FO, Catani L, Guidotti L, Melloni E, Maggiano N, Zauli G, Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 76349.
  • 33
    Cipollone F, Iezzi A, Iezzi M, Toniato E, Martinotti S, Rocca B, Ciabattoni G, Davì G, Fazia M, Pini B, Cuccurullo C, Paloscia L, Mascellanti M, Cuccurullo F, Patrono C, Mezzetti A. Aspirin-insensitive myocardial infarction is associated with overexpression of cyclooxygenase-2 in coronary thrombi [abstract]. Circulation 2004; 110: III76.
  • 34
    Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemostas 2003; 1: 17103.
  • 35
    Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 19807.
  • 36
    Patrono C, Bachmann F, Baigent C, Bode C, Charbonnier B, De Caterina R, Fitzgerald D, García Rodríguez LA, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Verheugt F, Vermylen J, Wallentin L. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 16681.
  • 37
    FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 11747.
  • 38
    Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 128794.
  • 39
    Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM. Molecular bases of defective signal transduction in platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003; 100: 197883.
  • 40
    Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 136672.
  • 41
    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 9615.
  • 42
    Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 31715.